UNITED STATES
 
 
SECURITIES AND EXCHANGE COMMISSION
 
 
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported): August 21, 2009
 
 
Ohr Pharmaceutical, Inc.
 
 
(Exact name of registrant as specified in its charter)
 
         
Delaware
  
333-88480
  
#04-3648721
(State or other Jurisdiction of Incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)

     
1245 Brickyard Road, Suite 590, Salt Lake City, Utah
  
84106
(Address of Principal Executive Offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (347)-753-4389
 
 
 
(Former name or former address if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 

Information to be included in the report

Item 1.01.  Entry into a Material Definitive Agreement.
 
On August 21, 2009, Ohr Pharmaceutical, Inc. (the “Company”) entered into an Asset Purchase Agreement with the Genaera Liquidating Trust for the acquisition by the Company of a group of clinical and pre-clinical compounds including associated patents, clinical data and inventory of finished compounds and raw materials.
 
Item 9.01. Financial Statements and Exhibits

(d) Exhibits

    Exhibit No.             Description
    - ---------------            - -------------------------------------------------------------------
10.1  
               Asset Purchase Agreement by and between the Company and the Genaera Liquidating Trust dated August 21, 2009.



 

 

 
 
 

 
Signature(s)
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Ohr Pharmaceutical, Inc.
 
 
Dated: August 26, 2009
 
By: /s/ Andrew Limpert                     
 
Andrew Limpert, President and CEO
 
 
 
 

 
 
 

Exhibit Index
 
Exhibit No.
  
Description
 
EX-10.1
 
 
Asset Purchase Agreement by and between the Company and the Genaera Liquidating Trust dated August 21, 2009.